JPWO2023164775A5 - - Google Patents
Info
- Publication number
- JPWO2023164775A5 JPWO2023164775A5 JP2024552478A JP2024552478A JPWO2023164775A5 JP WO2023164775 A5 JPWO2023164775 A5 JP WO2023164775A5 JP 2024552478 A JP2024552478 A JP 2024552478A JP 2024552478 A JP2024552478 A JP 2024552478A JP WO2023164775 A5 JPWO2023164775 A5 JP WO2023164775A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently
- optionally
- methyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316595P | 2022-03-04 | 2022-03-04 | |
| US63/316,595 | 2022-03-04 | ||
| PCT/CA2023/050280 WO2023164775A1 (en) | 2022-03-04 | 2023-03-03 | Radiolabeled compounds targetng the prostate-specific membrane antigen |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025507971A JP2025507971A (ja) | 2025-03-21 |
| JP2025507971A5 JP2025507971A5 (https=) | 2026-03-10 |
| JPWO2023164775A5 true JPWO2023164775A5 (https=) | 2026-03-10 |
Family
ID=87882764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552478A Pending JP2025507971A (ja) | 2022-03-04 | 2023-03-03 | 前立腺特異的膜抗原を標的とする放射性標識化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250186627A1 (https=) |
| EP (1) | EP4486756A1 (https=) |
| JP (1) | JP2025507971A (https=) |
| AU (1) | AU2023226956A1 (https=) |
| CA (1) | CA3244865A1 (https=) |
| WO (1) | WO2023164775A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210909A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| WO2025055943A1 (en) * | 2023-09-12 | 2025-03-20 | Shanghai Sinotau Biotech. Co., Ltd | Inhibitors of prostate specific membrane antigen and use thereof |
| CN121773094A (zh) * | 2023-09-12 | 2026-03-31 | 上海先通生物科技有限公司 | 前列腺特异性膜抗原的抑制剂和其用途 |
| WO2026002208A1 (zh) * | 2024-06-28 | 2026-01-02 | 思路迪生物医药(上海)有限公司 | 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3544960A1 (en) * | 2016-11-23 | 2019-10-02 | Cancer Targeted Technology LLC | Albumin-binding psma inhibitors |
| US11629201B2 (en) * | 2017-05-24 | 2023-04-18 | ITM Isotope Technologies Munich SE | PSMA-binding agents and uses thereof |
| CN114401947B (zh) * | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| US11850291B2 (en) * | 2019-10-25 | 2023-12-26 | National Atomic Research Institute | PSMA targeted radiotherapy medicine and preparation method thereof |
-
2023
- 2023-03-03 CA CA3244865A patent/CA3244865A1/en active Pending
- 2023-03-03 EP EP23762646.0A patent/EP4486756A1/en active Pending
- 2023-03-03 WO PCT/CA2023/050280 patent/WO2023164775A1/en not_active Ceased
- 2023-03-03 AU AU2023226956A patent/AU2023226956A1/en active Pending
- 2023-03-03 US US18/842,681 patent/US20250186627A1/en active Pending
- 2023-03-03 JP JP2024552478A patent/JP2025507971A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240140971A1 (en) | Psma targeted radiohalogenated ureas for cancer radiotherapy | |
| JP7207740B2 (ja) | 放射性薬剤 | |
| US8026273B2 (en) | 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient | |
| RU2008127312A (ru) | Мезилатное пролекарство леводопы, его композиции и применение | |
| CN110382508A (zh) | 用于抑制精氨酸酶活性的组合物和方法 | |
| RU97100789A (ru) | Новые производные замещенного пуринила, обладающие иммуномодуляторной активностью | |
| EP2255829A2 (en) | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as active ingredient | |
| JPWO2022228494A5 (https=) | ||
| JP7370520B2 (ja) | 放射性医薬 | |
| EP3890749A1 (en) | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| JPWO2020236825A5 (https=) | ||
| RU2000131184A (ru) | Соединения, обладающие свойствами, способствующими выделению гормона роста | |
| KR927003586A (ko) | 신규한 중추 작용성 6,7,8,9-테트라하이드로-3H-벤즈(e)인돌 헤테로사이클 화합물 | |
| JP2008506710A5 (https=) | ||
| JPWO2023164775A5 (https=) | ||
| JP2017516862A (ja) | アンドロゲン受容体調節物質及びその使用方法 | |
| WO2024140433A2 (zh) | 含n-亚甲基酰胺连接子的抗体-药物偶联物 | |
| WO2025246177A1 (zh) | 一种靶向fap的二聚化合物及其探针和应用 | |
| JPH10502081A (ja) | ホスフィン酸誘導体 | |
| JPWO2020106780A5 (https=) | ||
| US20170001957A1 (en) | Radioiodinated bioconjugation reagents | |
| CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
| RU2005125047A (ru) | Соединения карбоновых кислот | |
| EP1379499B1 (en) | New diaminedithiol derivatives and radiorhenium or radiotechnetium complex thereof; a liver cancer-treating composition comprising the radiorhenium complex and lipiodol; and a kit for preparation of the liver cancer-treating composition | |
| JPWO2022082312A5 (https=) |